According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
A number of other equities analysts have also weighed in on DOVA. Evercore ISI upgraded shares of Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 target price for the company in a research report on Monday, July 1st. Wedbush set a $190.00 target price on shares of Home Depot and gave the stock a hold rating in a research report on Wednesday, May 22nd. HC Wainwright increased their price objective on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a buy rating in a research report on Thursday, June 27th. Finally, BidaskClub upgraded shares of Zillow Group from a buy rating to a strong-buy rating in a research report on Tuesday, July 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $28.56.
Shares of NASDAQ:DOVA opened at $16.99 on Wednesday. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20. The stock’s fifty day moving average is $11.35. Dova Pharmaceuticals has a fifty-two week low of $5.62 and a fifty-two week high of $26.49. The company has a market capitalization of $472.90 million, a price-to-earnings ratio of -6.53 and a beta of 2.56.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. The firm had revenue of $4.00 million during the quarter, compared to analyst estimates of $3.46 million. Equities research analysts anticipate that Dova Pharmaceuticals will post -2.1 EPS for the current year.
In other Dova Pharmaceuticals news, insider Jason Hoitt sold 2,387 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $13.81, for a total transaction of $32,964.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 427,209 shares of the stock in a transaction on Friday, June 28th. The shares were acquired at an average price of $13.35 per share, with a total value of $5,703,240.15. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 582,854 shares of company stock valued at $8,243,825 and have sold 18,838 shares valued at $284,611. 60.30% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC lifted its position in Dova Pharmaceuticals by 0.8% during the first quarter. FMR LLC now owns 1,347,521 shares of the company’s stock valued at $11,979,000 after purchasing an additional 10,970 shares during the last quarter. Sanders Morris Harris LLC lifted its position in Dova Pharmaceuticals by 85.1% during the second quarter. Sanders Morris Harris LLC now owns 521,887 shares of the company’s stock valued at $7,359,000 after purchasing an additional 239,972 shares during the last quarter. Broadfin Capital LLC bought a new position in Dova Pharmaceuticals during the fourth quarter valued at $2,667,000. Sphera Funds Management LTD. lifted its position in Dova Pharmaceuticals by 54.2% during the fourth quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock valued at $1,402,000 after purchasing an additional 65,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Dova Pharmaceuticals by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock valued at $1,184,000 after purchasing an additional 11,732 shares during the last quarter. Institutional investors and hedge funds own 30.18% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.